Carlo Incerti - 18 Nov 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Director
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol: DYN
Transactions as of: 18 Nov 2024
Net transactions value: -$330,660
Form type: 4
Filing time: 18 Nov 2024, 19:42:09 UTC
Previous filing: 24 May 2024
Next filing: 03 Jun 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Options Exercise	$143,385	+16,500		$8.69	16,500	18 Nov 2024	Direct
transaction	DYN	Common Stock	Sale	$474,045	-16,500	-100%	$28.73	0	18 Nov 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock option (right to buy)	Options Exercise	$0	-16,500	-42%	$0.000000	22,693	18 Nov 2024	Common Stock	16,500	$8.69	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.47 to $29.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F2	The option was granted on March 2, 2022. The shares underlying the option are scheduled to vest over three years in equal monthly installments through March 2, 2025.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.47 to $29.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

The option was granted on March 2, 2022. The shares underlying the option are scheduled to vest over three years in equal monthly installments through March 2, 2025.